Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Oct 31;113(1):1-5.
doi: 10.1016/j.imlet.2007.07.008. Epub 2007 Aug 22.

Mimotope vaccines: epitope mimics induce anti-cancer antibodies

Angelika B Riemer  1 , Erika Jensen-Jarolim
Affiliations
Review

Mimotope vaccines: epitope mimics induce anti-cancer antibodies

Angelika B Riemer et al. Immunol Lett. .

Abstract

Mimotopes are epitope-mimicking structures. When applied for immunizations they induce desired antibody specificities exclusively based on the principle of molecular mimicry. This is important as antibodies directed against tumor-associated antigens may harbor diverse biological effects depending on their epitope specificity. Thus they may inhibit or promote tumor growth. This review gives an update on different vaccination strategies based on the mimotope concept.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The principle of a tumor mimotope vaccine. Mimotopes are epitope-mimicking structures suitable for vaccination. They may be linear or circular peptides (as depicted), or anti-idiotypic antibodies. By virtue of molecular mimicry these mimotopes can induce antibodies not only directed against the immunogen, but also towards the natural epitope expressed or overexpressed on a cancer cell. The antibody response is polyclonal and acts cytotoxic against tumor cells by exploiting several effector functions.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–7. - PubMed
    1. Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525–31. - PubMed
    1. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181–273. - PubMed
    1. Yarden Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci USA. 1990;87:2569–73. - PMC - PubMed
    1. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA. 1991;88:8691–5. - PMC - PubMed

Publication types

MeSH terms